GMAB GMAB
Company Profile ↓Company Overview
GMAB (GMAB) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 21.2% CAGR over the past five years.
Maintains a net profit margin of 25.9%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $3.72B (+19.2% YoY); net profit $963.00M.
- Trailing 12 Months Year-on-year growth — revenue +19.2%, earnings -15.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 21.2%, profit CAGR 7.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 21.23% |
| 1 Year: | 19.19% |
Compounded Profit Growth
| 5 Years: | 7.06% |
| 1 Year: | -15.00% |
Stock Price Performance
| 1 Year: | +33.12% |
| 6 Months: | -11.41% |
| 3 Months: | +6.32% |
| 1 Month: | +0.27% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)60.12 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 25.9%.
- Compounding revenue at 21.2% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 715.00M | 925.00M | 1.02B | 1.06B | 896.00M |
| Cost of Revenue | 42.00M | 57.00M | 58.00M | 81.00M | 65.00M |
| Gross Profit | 673.00M | 868.00M | 964.00M | 977.00M | 831.00M |
| Operating Expenses | 485.00M | 508.00M | 505.00M | 734.00M | 606.00M |
| Operating Income | 188.00M | 360.00M | 459.00M | 243.00M | 225.00M |
| EBITDA | 265.00M | 448.00M | 503.00M | 120.00M | 215.00M |
| Interest Expense | 5.00M | 9.00M | 3.00M | 44.00M | 112.00M |
| Pretax Income | 244.00M | 423.00M | 482.00M | 55.00M | 74.00M |
| Tax Provision | 49.00M | 87.00M | 81.00M | 24.00M | 21.00M |
| Net Income | 195.00M | 336.00M | 401.00M | 31.00M | 53.00M |
| Diluted EPS | 0.30 | 0.54 | 0.65 | - | 0.08 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 2.09B | 2.39B | 3.12B | 3.72B |
| Cost of Revenue | 0 | 33.00M | 143.00M | 238.00M |
| Gross Profit | 2.09B | 2.36B | 2.98B | 3.48B |
| Operating Expenses | 1.19B | 1.58B | 1.96B | 2.23B |
| Operating Income | 902.00M | 772.00M | 1.01B | 1.25B |
| EBITDA | 1.06B | 870.00M | 1.40B | 1.34B |
| Interest Expense | 5.61M | 10.00M | 18.00M | 61.00M |
| Pretax Income | 999.58M | 817.00M | 1.33B | 1.20B |
| Tax Provision | 214.89M | 186.00M | 193.00M | 241.00M |
| Net Income | 784.70M | 631.00M | 1.13B | 963.00M |
| Diluted EPS | 1.20 | 0.96 | 1.69 | 1.54 |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 563.05M | 1.07B | 1.13B | 1.19B |
| Investing Cash Flow | - | -397.39M | -185.00M | -1.45B | -5.64B |
| Financing Cash Flow | - | -113.56M | -89.00M | -566.00M | 4.79B |
| Capital Expenditure | - | -45.63M | -54.00M | -44.00M | -55.00M |
| Free Cash Flow | - | 517.42M | 1.02B | 1.08B | 1.13B |
| Net Change in Cash | - | 52.10M | 797.00M | -887.00M | 332.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 100.0% | 98.6% | 95.4% | 93.6% |
| Operating Margin % | 43.2% | 32.3% | 32.5% | 33.6% |
| Net Margin % | 37.6% | 26.4% | 36.3% | 25.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GMAB
How Investors Are Reacting To Genmab (CPSE:GMAB) Epcoritamab’s Phase 3 Overall-Survival Miss in DLBCL - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxNRVJtVktTNzItbDFCSjRaaWpWcjJjVW9naDNtcGlwZXVOb1BUanhHemdfV0N6UjZwaXc3V1dpV1VKU2hZTlh6YmtpOWdrTUtva2NyZXQ5c2NxSHVXZF9yS0lLUlk4TkR6eU5PYmZ1QWRIMEZqM1NpcmhtT085T2pGb0U2YzBxMUtWX1dwX2…
Genmab A/S Q1 2026 Earnings Call Transcript - MarketBeat
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE1xanlWblpoR0F1NzlQZ19LcUFXbFk5NC1hRXJ5OGRyUE4weDlCLVFIbm5IOHRxZkNqZTZkbEVkdzRweFptMXdfMkNvQzVOYmNtWVdEVUp3MXBSVWVJcUJUMzZqZEpHbzRxY3ZSM3gzLXpGQnJJd1dSdw?oc=5" target="_blank">Genma…
Genmab A/S (GMAB) stock falls on Q1 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNaUh6a2RmMnNjNFB2VnI3MTNTTGlfWTl6WExfRFhzRHRJOHJhdzhYbkNld0NaLUFpekFfemdPbmdSM1pCaG5hcEZTaGQ2WEhZWGJqSXZReWh0djNMZDlrUjZQSWZVbHJaRERwQ0dpRkFBclBZZ29HT1Fvc2VueFFvMG8wR2hMUEZKeDIzZl…
Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Softness And 24.6% Undervaluation Estimate - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNLWV6MExvM1NSUEJ5eE5CaU1tZERrby1IaFFnN2IxR2xpWFo0NjVZczY1VUkyT3g4NWI5TU8tMm5iaGVQdU90eEVmMXhoRzhzQnBBd3hSTUdHaTJRSFo3REJHLUpLWjRPSVRPYVNlOFl5SGc5d0VCM1Q2b3JmZ29DOGFla0RManlPdFR4bE…
Genmab A/S (GMAB) Stock Analysis: 31% Potential Upside Ignites Investor Interest - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxPT0JnNHVXSVRlblBsR0I1SXZEQTNMRW1iUlFzZEhoeXpoQUF3QlpiSXE5QTBjempKbXdsbW0xOGdDTS1yNDk2Q0F6VXpvcEFYZkNIUDdQR0lRQUw4MnUxUW5OamdtdjhRaUlnczkzMm12eGNmUmV3MFFJNE5IU2ZvLWdjOExpbzVMc0lOZD…
Genmab's H1 Preview: Darzalex Beats The Sales Outlook - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPNFRiY3ZTYmpqc090OXRTc3QtS29wMWREbF9yZUJlbEtOUmNiVVdhbVhOSWRJNDF3NzNDVVRjN3Bwc3habkhadWk1N2lpSHloUl8ybnQtOXVNdFFMeFR5bVVDUnIxOHhBSVcyUmZON1JvYm9DMFhwaGlGVGd4aDJjWE1tUzh0ZzlCbzl0NV…
GMAB — Frequently Asked Questions
What is the current share price of GMAB?
As of 2026-08-05 17:25 PDT, GMAB trades at $29.26 on NASDAQ/NYSE. Its 52-week range is $21.08 to $35.34.
What is the P/E ratio of GMAB?
GMAB trades at a trailing price-to-earnings (P/E) ratio of 19.04.
Is GMAB a good stock to buy?
This page provides a data-driven analysis of GMAB, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.